B-cell non Hodgkins lymphomas
Principal investigator: Harald Holte MD,PhD, Department of Oncology, DNR
Chimerical anti-CD20 monoclonal antibody (Mabtheraâ) in remission induction and maintenance treatment of relapsed follicular non-Hodgkins lymphoma: a phase III randomised clinical trial. Intergroup collaborative study (EORTC 20 981)
Disease: relapsed follicular non Hodgkin`s lymphoma
Collaboration partners: Nordic Lymphoma Group.
Randomise Intergroup Trial of first line treatment for patients with diffuse large B-cell non-Hodgkins lymphoma with a CHOP-like chemotherapy regimen with or without the anti-CD20 antibody Rituximab (IDEC-C2B8) (Trial M39045).
Collaboration partners: Nordic Lymphoma group
Protocol to be started:
Rituximab (Mabthera) as single agent and or in combination with interferon-a2a as primary treatment follicular lymphomas. A randomised phase III study.
Disease: primary follicular non Hodgkin`s lymphoma
Collaboration partners: Nordic Lymphoma GroupDisease: diffuse large B-cell non Hodgkin`s Lymphoma
Chimerical anti-CD20 monoclonal antibody (Mabtheraâ) in remission induction and maintenance treatment of relapsed follicular non-Hodgkins lymphoma: a phase III randomised clinical trial. Intergroup collaborative study (EORTC 20 981)
Disease: relapsed follicular non Hodgkin`s lymphoma
Collaboration partners: Nordic Lymphoma Group.
Randomise Intergroup Trial of first line treatment for patients with diffuse large B-cell non-Hodgkins lymphoma with a CHOP-like chemotherapy regimen with or without the anti-CD20 antibody Rituximab (IDEC-C2B8) (Trial M39045).
Collaboration partners: Nordic Lymphoma group
Protocol to be started:
Rituximab (Mabthera) as single agent and or in combination with interferon-a2a as primary treatment follicular lymphomas. A randomised phase III study.
Disease: primary follicular non Hodgkin`s lymphoma
Collaboration partners: Nordic Lymphoma GroupDisease: diffuse large B-cell non Hodgkin`s Lymphoma